皮肤T细胞淋巴瘤中I类HLA的基因改变
研究对65例晚期蕈样肉芽肿或Sézary综合征患者进行靶向DNA测序,发现26例(40%)存在至少1种I类HLA异常,包括9例共12种独特体细胞HLA突变及24例杂合性缺失或双等位基因缺失。HLA异常与其他免疫逃逸事件共存并与更差的无进展生存相关,单细胞分析显示HLA异常常为亚克隆性,系列样本分析显示其动态变化,1例接受帕博利珠单抗耐药患者中耐药与HLA突变消除相关。
要点
- 晚期CTCL中I类HLA基因异常常见,65例中26例(40%)存在至少1种异常。
- HLA异常常为亚克隆性,可动态变化,并与更差的无进展生存相关。
- 1例帕博利珠单抗耐药与HLA突变消除相关,提示HLA异常可能影响免疫治疗。
核心结论
- 基因组I类HLA异常在晚期CTCL中常见,可能是理解CTCL免疫治疗效应的重要考虑因素。
研究设计与样本
- 对65例晚期蕈样肉芽肿或Sézary综合征患者进行靶向DNA测序(覆盖HLA位点),并开展单细胞分析和系列样本分析。
主要发现
- 65例中26例(40%)存在至少1种HLA异常。
- 9例患者中发现12种独特体细胞HLA突变,24例存在HLA杂合性缺失或双等位基因缺失。
- HLA异常 preferentially 破坏能够呈递更多推测新抗原的HLA等位基因,且未伴随I类HLA总表达下降。
- HLA异常与其他遗传免疫逃逸事件共存,并与更差的无进展生存相关。
- 单细胞分析显示HLA异常常为亚克隆性;系列样本分析显示破坏I类HLA的事件随疾病进程动态变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Abnormalities involving class I HLA are frequent in many lymphoma subtypes but have not yet been extensively studied in cutaneous T-cell lymphomas (CTCLs). We characterized the occurrence of class I HLA abnormalities in 65 patients with advanced mycosis fungoides or Sézary syndrome. Targeted DNA sequencing, including coverage of HLA loci, revealed at least 1 HLA abnormality in 26 of 65 patients (40%). Twelve unique somatic HLA mutations were identified across 9 patients, and loss of heterozygosity or biallelic loss of HLA was found to affect 24 patients. Although specific HLA alleles were commonly disrupted, these events did not associate with a decrease in the total class I HLA expression. Genetic events preferentially disrupted HLA alleles capable of presenting greater numbers of putative neoantigens. HLA abnormalities co-occurred with other genetic immune evasion events and were associated with worse progression-free survival. Single-cell analyses demonstrated that HLA abnormalities were frequently subclonal. Through analysis of serial samples, we observed that disrupting class I HLA events change dynamically over the disease course. The dynamics of HLA disruption are highlighted in a patient who received pembrolizumab and in whom resistance to pembrolizumab was associated with the elimination of an HLA mutation. Overall, our findings show that genomic class I HLA abnormalities are common in advanced CTCL and may be an important consideration in understanding the effects of immunotherapy in CTCL.
引用
- Kwang AC, Duran GE, Fernandez-Pol S, et al. Genetic alteration of class I HLA in cutaneous T-cell lymphoma. Blood. 2025. PMID: 39388712. doi:10.1182/blood.2024024817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。